FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

Merck has secured FDA approval for KEYTRUDA QLEX, the first and only subcutaneous immune checkpoint inhibitor, covering most solid tumor indications currently treated by its intravenous KEYTRUDA. This new formulation offers significant patient and healthcare provider convenience, allowing for one-minute administration by a healthcare professional in various settings with demonstrated comparable efficacy to the IV version. Expected to launch in the U.S. in late September, this development could expand market access and strengthen Merck's oncology franchise by improving treatment flexibility and patient experience.

Analysis

Merck has secured a significant FDA approval for KEYTRUDA QLEX, a subcutaneous (sub-Q) formulation of its blockbuster immunotherapy, KEYTRUDA. This approval is pivotal as it establishes the first sub-Q immune checkpoint inhibitor, drastically reducing administration time to as little as one minute compared to the 30-minute intravenous (IV) infusion. The approval is supported by a Phase 3 trial in non-small cell lung cancer (NSCLC) which demonstrated comparable pharmacokinetic exposure and efficacy to the IV version, with similar overall response rates (45% for QLEX vs. 42% for IV KEYTRUDA) and no notable differences in overall or progression-free survival. This new formulation, which covers 38 of KEYTRUDA's solid tumor indications, enhances convenience for both patients and healthcare providers and expands potential treatment settings beyond specialized infusion centers to include doctor's offices and local clinics. With a U.S. launch planned for late September, this strategic product line extension is poised to fortify KEYTRUDA's market leadership, improve patient experience, and create a competitive moat for Merck's cornerstone oncology franchise.

Key Decisions for Investors

• View this approval as a major positive for Merck, as it provides a robust life-cycle management strategy for its flagship KEYTRUDA franchise, likely preserving significant revenue and market share against future competition.
• Investors should monitor the initial commercial uptake and formulary acceptance of KEYTRUDA QLEX following its late September launch, as the pace of adoption by oncologists will be a key indicator of its ability to defend the franchise.
• While efficacy and safety profiles are comparable to the IV formulation, it is prudent to note the extensive list of potential adverse reactions, which remains a key consideration for the entire PD-1/PD-L1 drug class.